Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2026 16:15 ET | Source: Neuphoria Therapeutics, Inc.

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria”...
June 26, 2026 16:15 ET | Source: Futurewave Acquisition Corporation

Futurewave Acquisition Corporation Announces Closing of Initial Public Offering

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Acquisition Corp (Nasdaq: FWACU, the “Company”) announced today that it closed its initial public offering (“IPO”) of 8,625,000 units at an offering price...
June 26, 2026 16:05 ET | Source: Universe Pharmaceuticals INC.

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in...
June 26, 2026 16:05 ET | Source: Alpex Acquisition Corp

Alpex Acquisition Corporation Announces Closing of $115,000,000 Initial Public Offering, Including Full Exercise of Over-allotment Option

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Alpex Acquisition Corporation (NASDAQ: ALPXU) (the “Company”), a Cayman Islands exempted company, announced today the closing of its initial public...
June 26, 2026 16:05 ET | Source: Monopar Therapeutics Inc.

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...
June 26, 2026 16:05 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company...
June 26, 2026 16:01 ET | Source: Lantheus Holdings, Inc.

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians...
June 26, 2026 16:01 ET | Source: Ascendis Pharma

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap...
June 26, 2026 15:13 ET | Source: REalloys Inc.

REalloys Inc. (Nasdaq: ALOY) Announces Closing of $100 Million Private Placement

REalloys Announces Closing of $100 Million Private Placement
June 26, 2026 14:49 ET | Source: Rocket Lab Corporation

Rocket Lab Completes 10th Consecutive Launch with 100% Mission Success for Synspective

MAHIA, New Zealand, June 26, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today announced it has successfully placed another...